1
|
Jiang Y, Sun Z, Ge Z, Tao Z, Liu M, Zhong W, Dong N, Xu L, Wang H, Xu Y, Shen X. Differential expression of Semaphorin-7A /CD163-positive macrophages in large artery and cardiogenic stroke. BMC Neurol 2024; 24:70. [PMID: 38373967 PMCID: PMC10875813 DOI: 10.1186/s12883-024-03559-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2023] [Accepted: 02/01/2024] [Indexed: 02/21/2024] Open
Abstract
BACKGROUND Identification of the causes of stroke of undetermined etiology, specifically cardioembolism (CE) and non-CE causes, can inform treatment planning and prognosis prediction. The objective of this study was to analyze the disparities in thrombus composition, particularly Semaphorin-7A (Sema7A) and CD163, between patients diagnosed with large-artery atherosclerosis (LAA) and those with CE, and to investigate their potential association with prognosis. METHODS Thrombi were collected from patients who underwent mechanical thrombectomy at two hospitals. The patients were categorized into two groups: LAA and CE. We compared the levels of Sema7A and CD163 between these groups and analyzed their relationships with stroke severity, hemorrhagic transformation and prognosis. RESULTS The study involved a total of 67 patients. Sema7A expression was found to be significantly higher in the CE group compared to LAA (p < 0.001). Conversely, no statistically significant differences were observed for CD163 between the groups. The presence of Sema7A/CD163 did not show any associations with stroke severity or hemorrhagic transformation (all p > 0.05). However, both Sema7A (OR, 2.017; 95% CI, 1.301-3.518; p = 0.005) and CD163 (OR, 2.283; 95% CI, 1.252-5.724; p = 0.03) were associated with the poor prognosis for stroke, after adjusting for stroke severity. CONCLUSION This study highlights that CE thrombi exhibited higher levels of Sema7A expression compared to LAA thrombi. Moreover, we found a positive correlation between Sema7A/CD163 levels and the poor prognosis of patients with acute ischemic stroke.
Collapse
Affiliation(s)
- Yi Jiang
- Department of Geriatrics, Bengbu Medical College Clinical College of Lianyungang Second People's Hospital, Lianyungang, 222000, China
| | - Zhichao Sun
- Department of Pathology, Lianyungang Second People's Hospital, Lianyungang, 222000, China
| | - Zhonglin Ge
- Department of Neurology, Lianyungang Second People's Hospital, Lianyungang, 222000, China.
| | - Zhonghai Tao
- Department of Neurology, Lianyungang Second People's Hospital, Lianyungang, 222000, China
| | - Mengqian Liu
- Department of Geriatrics, Lianyungang Hospital Affiliated to Jiangsu University, Lianyungang, 222000, China
| | - Wen Zhong
- Department of Geriatrics, Lianyungang Hospital Affiliated to Jiangsu University, Lianyungang, 222000, China
| | - Nan Dong
- Department of Neurology, Shaoxing Central Hospital, Shaoxing, China
| | - Lei Xu
- Department of Pathology, Lianyungang Second People's Hospital, Lianyungang, 222000, China
| | - Hui Wang
- Department of Neurology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Yiwen Xu
- Department of Infectious Disease, The First Affiliated Hospital of Ningbo University, Ningbo, China
| | - Xiaozhu Shen
- Department of Geriatrics, Bengbu Medical College Clinical College of Lianyungang Second People's Hospital, Lianyungang, 222000, China.
| |
Collapse
|
2
|
Lu Q, Liu Z, Zhao L, Xu L, Liu C, Li L, Cao Y, Li F, Wu L, Wang L, Chen T, You T, Ren L, Wang G, Tang C, Zhu L. Sema7A protects against high-fat diet-induced obesity and hepatic steatosis by regulating adipo/lipogenesis. Mol Metab 2023; 70:101698. [PMID: 36842496 PMCID: PMC10009717 DOI: 10.1016/j.molmet.2023.101698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2023] [Revised: 02/20/2023] [Accepted: 02/20/2023] [Indexed: 02/28/2023] Open
Abstract
OBJECTIVE Obesity and related diseases are becoming a growing risk for public health around the world due to the westernized lifestyle. Sema7A, an axonal guidance molecule, has been known to play a role in neurite growth, bone formation, and immune regulation. Whether Sema7A participates in obesity and metabolic diseases is unknown. As several SNPs in SEMA7A and its receptors were found to correlate with BMI and metabolic parameters in the human population, we investigated the potential role of Sema7A in obesity and hepatic steatosis. METHODS GWAS and GEPIA database was used to analyze SNPs in SEMA7A and the correlation of Sema7A expression with lipid metabolism related genes. Sema7A-/- mice and recombinant Sema7A (rSema7A) were used to study the role of Sema7A in HFD-induced obesity and hepatic steatosis. Adipose tissue-derived mesenchymal stem cells (ADSCs) were used to examine the role of Sema7A in adipogenesis, lipogenesis and downstream signaling. RESULTS Deletion of Sema7A aggravated HFD-induced obesity. Sema7A deletion enhanced adipogenesis in both subcutaneous and visceral ADSCs, while the addition of rSema7A inhibited adipogenesis of ADSCs and lipogenesis of differentiated mature adipocytes. Sema7A inhibits adipo/lipogenesis potentially through its receptor integrin β1 and downstream FAK signaling. Importantly, administration of rSema7A had protective effects against diet-induced obesity in mice. In addition, deletion of Sema7A led to increased hepatic steatosis and insulin resistance in mice. CONCLUSIONS Our findings reveal a novel inhibitory role of Sema7A in obesity and hepatic steatosis, providing a potential new therapeutic target for obesity and metabolic diseases.
Collapse
Affiliation(s)
- Qiongyu Lu
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Ziting Liu
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Luyao Zhao
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Linru Xu
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Chu Liu
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Ling Li
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Yiren Cao
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Fengchan Li
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Lili Wu
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Lei Wang
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Ting Chen
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Tao You
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Lijie Ren
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China
| | - Guixue Wang
- JinFeng Laboratory, Chongqing, China; Key Laboratory of Biorheological and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, China
| | - Chaojun Tang
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China; National Clinical Research Center for Hematologic Diseases at the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China; The Ninth Affiliated Hospital, Soochow University, Suzhou, Jiangsu, China; JinFeng Laboratory, Chongqing, China.
| | - Li Zhu
- Cyrus Tang Medical Institute, Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology of Jiangsu Province, Suzhou Key Lab of Thrombosis and Hemostasis, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, China; National Clinical Research Center for Hematologic Diseases at the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China; The Ninth Affiliated Hospital, Soochow University, Suzhou, Jiangsu, China; JinFeng Laboratory, Chongqing, China.
| |
Collapse
|
3
|
Shapoori S, Mosayebi G, Ebrahimi Monfared M, Ghazavi A, Khansarinejad B, Farahani I, Ganji A. Gene expression of semaphorin-3A, semaphorin-7A, neuropilin-1, plexin-C1, and β1 integrin in treated-multiple sclerosis patients. Neurol Res 2020; 42:783-788. [PMID: 32497464 DOI: 10.1080/01616412.2020.1774211] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
OBJECTIVE Recently, members of the semaphorin family have received major attention in various medical fields, especially autoimmunity. In this study, we selected semaphorin-3A (Sema3A), semaphorin-7A (Sema7A), and their receptors to determine the possible relationship between these molecules and multiple sclerosis (MS). METHOD We measured the gene expression of Sema3A, Sema7A, neuropilin-1 (NP-1), plexin-C1, and β1 integrin in the blood samples of relapsing-remitting multiple sclerosis (RRMS) patients, treated with high-dose interferon-β1a (IFN-β1a), low-dose IFN-β1a, IFN-β1b, and glatiramer acetate (GA) via quantitative real-time polymerase chain reaction (qRT-PCR) assay, and then, compared the results of treatment-naive patients with the healthy controls. RESULTS The gene expression of Sema3A (P = 0.02), NP-1 (P < 0.001), and plexin-C1 (P < 0.01) significantly decreased in the treatment-naive group, compared to the healthy controls. Sema3A significantly increased in all treated patients, compared to the treatment-naive patients (P < 0.001). However, expression of NP-1 (P < 0.001), plexin-C1 (P < 0.001), and β1 integrin (P < 0.05) only increased in patients receiving high-dose IFN-β1a, IFN-β1b, and GA. Expression of Sema7A increased in only two groups of patients treated with IFN-β1b (P < 0.001) and GA (P = 0.018), without any significant decrease in the treatment-naive group, compared to the healthy controls (P > 0.05). CONCLUSION Our findings confirm that the presence of Sema3A, Sema7A, and their receptors can play critical roles in the treatment of MS patients. Therefore, they can be potential target molecules for MS treatment in the future.
Collapse
Affiliation(s)
- Shima Shapoori
- Department of Microbiology and Immunology, School of Medicine, Arak University of Medical Sciences , Arak, Iran
| | - Ghasem Mosayebi
- Department of Microbiology and Immunology, School of Medicine, Arak University of Medical Sciences , Arak, Iran.,Molecular and Medicine Research Center, Arak University of Medical Sciences , Arak, Iran
| | | | - Ali Ghazavi
- Department of Microbiology and Immunology, School of Medicine, Arak University of Medical Sciences , Arak, Iran.,Traditional and Complementary Medicine Research Center (TCMRC), Department of Microbiology and Immunology, School of Medicine, Arak University of Medical Sciences , Arak, Iran
| | - Behzad Khansarinejad
- Department of Microbiology and Immunology, School of Medicine, Arak University of Medical Sciences , Arak, Iran.,Molecular and Medicine Research Center, Arak University of Medical Sciences , Arak, Iran
| | - Iman Farahani
- Department of Microbiology and Immunology, School of Medicine, Arak University of Medical Sciences , Arak, Iran
| | - Ali Ganji
- Department of Microbiology and Immunology, School of Medicine, Arak University of Medical Sciences , Arak, Iran.,Molecular and Medicine Research Center, Arak University of Medical Sciences , Arak, Iran
| |
Collapse
|
4
|
Pham TL, He J, Kakazu AH, Jun B, Bazan NG, Bazan HEP. Defining a mechanistic link between pigment epithelium-derived factor, docosahexaenoic acid, and corneal nerve regeneration. J Biol Chem 2017; 292:18486-18499. [PMID: 28972155 PMCID: PMC5682960 DOI: 10.1074/jbc.m117.801472] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2017] [Revised: 09/22/2017] [Indexed: 12/22/2022] Open
Abstract
The cornea is densely innervated to sustain the integrity of the ocular surface. Corneal nerve damage produced by aging, diabetes, refractive surgeries, and viral or bacterial infections impairs tear production, the blinking reflex, and epithelial wound healing, resulting in loss of transparency and vision. A combination of the known neuroprotective molecule, pigment epithelium–derived factor (PEDF) plus docosahexaenoic acid (DHA), has been shown to stimulate corneal nerve regeneration, but the mechanisms involved are unclear. Here, we sought to define the molecular events of this effect in an in vivo mouse injury model. We first confirmed that PEDF + DHA increased nerve regeneration in the mouse cornea. Treatment with PEDF activates the phospholipase A2 activity of the PEDF-receptor (PEDF-R) leading to the release of DHA; this free DHA led to enhanced docosanoid synthesis and induction of bdnf, ngf, and the axon growth promoter semaphorin 7a (sema7a), and as a consequence, their products appeared in the mouse tears. Surprisingly, corneal injury and treatment with PEDF + DHA induced transcription of neuropeptide y (npy), small proline-rich protein 1a (sprr1a), and vasoactive intestinal peptide (vip) in the trigeminal ganglia (TG). The PEDF-R inhibitor, atglistatin, blocked all of these changes in the cornea and TG. In conclusion, we uncovered here an active cornea–TG axis, driven by PEDF-R activation, that fosters axon outgrowth in the cornea.
Collapse
Affiliation(s)
- Thang Luong Pham
- From the Department of Ophthalmology and Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, Louisiana 70112-2223
| | - Jiucheng He
- From the Department of Ophthalmology and Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, Louisiana 70112-2223
| | - Azucena H Kakazu
- From the Department of Ophthalmology and Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, Louisiana 70112-2223
| | - Bokkyoo Jun
- From the Department of Ophthalmology and Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, Louisiana 70112-2223
| | - Nicolas G Bazan
- From the Department of Ophthalmology and Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, Louisiana 70112-2223
| | - Haydee E P Bazan
- From the Department of Ophthalmology and Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, Louisiana 70112-2223
| |
Collapse
|